Xarelto Ad’s Benefit Claims Need Renal Caveats, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Typography and graphics which highlight benefits but not risks makes a print ad for Xarelto to treat atrial fibrillation misleading, FDA tells Johnson & Johnson in an untitled letter.